A Study of Neurofeedback for the Treatment of Parkinson's Disease

A Phase 1 Double-Blind Crossover Comparative Study of Neurofeedback for the Treatment of Parkinson's Disease

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03837548

Enrollment

Registered

2019-02-12

Start date

2019-06-01

Completion date

2022-03-31

Last updated

2019-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

Parkinson's Disease, Magnetoencephalography, Neurofeedback

Brief summary

This study aims to reveal relationship between brain activities and the symptoms of Parkinson disease when a neurofeedback training was applied for them.

Interventions

OTHERTraining with Neurofeedback

Neurofeedback the brain activities by Magnetoencephalography

OTHERThe other Training with Neurofeedback

Neurofeedback the brain activities by Magnetoencephalography

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

* Subjects with age more than 20 * Subjects obtained the consent * Subjects with Parkinson disease and healthy subjects

Exclusion criteria

* The subjects who can not conduct the tasks * Subjects with severe illness * Subjects whom the experimenter think as in appropriate * Subjects with implantable devices such as pacemaker

Design outcomes

Primary

Measure	Time frame	Description
Alteration of Brain Activities	At the time Immediately following the training	measured by magnetoencephalography

Secondary

Measure	Time frame	Description
The raw score change from baseline in the Movement disorder society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part Ⅲ scores	At the time Immediately following the training	MDS-UPDRS retains the four-scale structure with a reorganization of the various subscales. The scales are now titled; (Part I) nonmotor experiences of daily living (13 items), (Part II) motor experiences of daily living (13 items), (Part III) motor examination (18 items), and (Part IV) motor complications (six items). Each subscale now has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. The total score is the sum of the subscale scores for Part III and ranges from 0 (no disability) to 132 (total dependence).

Countries

Japan

Contacts

Primary ContactTakufumi Yanagisawa, Ph.D.

tyanagisawa@nsurg.med.osaka-u.ac.jp+81-6-6879-3652

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026